Objective-The identification of platelet-reactive proteins exclusively present in atherosclerotic plaques could provide interesting targets for effective and safe antithrombotic strategies. In this context, we explored platelet adhesion and activation to tenascin-C (TN-C), a matrix protein preferentially found within atheroma. Methods and Results-We show that platelets efficiently adhere to TN-C under both static and flow conditions. Videomicroscopy revealed a unique behavior under flow, with platelets exhibiting stationary adhesion to TN-C; in contrast, platelets rolled over von Willebrand factor and detached from fibrinogen. Platelet interaction with TN-C was predominantly supported by integrin ␣ 2 ␤ 1 under static conditions, whereas under high shear, it was dependent on both the ␣ 2 ␤ 1 integrin and the glycoprotein Ib-IX complex. Integrin ␣ IIb ␤ 3 appeared to play a secondary role but only at low shear rates. The glycoprotein Ib-IX-dependent interaction was indirect, relying on von Willebrand factor, and increased as a function of wall shear rate. Von Willebrand factor bound directly to TN-C, as shown by ELISA and coimmunoprecipitation, suggesting that it acts as a bridge between TN-C and platelets. The adhesion of platelets to TN-C triggered their activation, as demonstrated by a shape change and increases in intracellular calcium level. Conclusion-This study provides evidence that TN-C serves as a novel adhesive matrix for platelets in a context that is relevant to atherothrombosis. (Arterioscler Thromb Vasc Biol. 2011;31:117-124.)
T he central role of platelets in arterial thrombosis renders them attractive targets for antithrombotic drugs. Clopidogrel and integrin ␣ IIb ␤ 3 blockers, 2 antiplatelet agents widely used in clinical practice, have greatly reduced cardiovascular-associated death; however, because they directly target the hemostatic function of platelets, their use is linked to an increased bleeding risk. The development of more selective antithrombotic drugs causing minimal perturbation of hemostasis could pave the way to new and more effective strategies in the treatment of ischemic events. This task is challenged by the fact that the main cellular and molecular events implicated in thrombosis are also those regulating hemostasis. Nevertheless, differences exist between these 2 conditions, such as the rheological microenvironment and the nature of the vascular material exposed to platelets. Thrombosis occurs in advanced atherosclerotic arteries that present abnormal luminal narrowing or stenosis inducing local disturbance of blood flow. 1 In addition, the marked inflammation and active tissue remodeling found in atheroma profoundly modify the composition of the subendothelium. Atherosclerotic plaques are rich in highly reactive platelet-adhesive materials, such as collagens or lipids, and overexpress extracellular matrix proteins that are essentially absent from the healthy vessel wall. The identification of platelet-adhesive proteins preferentially expressed in diseased vessels could provide novel targets for more selective antithrombotic therapies.
In this context, tenascin-C (TN-C) appears to be an interesting candidate because it is highly expressed in mouse and human advanced atherosclerotic plaques, whereas it is much less present in healthy vessels. [2] [3] [4] By using a TN-Cspecific antibody, we confirmed a previous observation that the plaques located in the carotid arteries of 30-week-old apolipoprotein E-deficient mice present strong expression of TN-C (supplemental Figure I ; all supplemental material available online at http://atvb.ahajournals.org). 3 In contrast, we detected a much weaker TN-C signal in the carotid arteries of wild-type mice and in the healthy portions of apolipoprotein E-deficient vessels, suggesting that this pro-tein could be more relevant to pathological thrombosis than to normal hemostasis. The role of TN-C in atherosclerosis is not clearly defined, but this matrix protein could participate in plaque destabilization. 2 Because TN-C has been localized close to the ruptured areas of advanced plaques, it could be exposed to circulating blood and platelets upon plaque rupture.
TN-C is a large glycoprotein (GP) found in the extracellular matrix of vertebrate organisms that modulates cellular responses. 5 It is produced at high levels during embryogenesis but is almost absent in adulthood. However, this protein is strongly reexpressed in tissues undergoing remodeling, such as during wound healing or in pathological states, including tumor progression and inflammation. 5 TN-C has been implicated in the modulation of cell adhesion, migration, growth, and apoptosis. Although often reported as an antiadhesive protein, TN-C has been described to support the adhesion of endothelial cells through integrins, including ␣ v ␤ 3 and ␣ 2 ␤ 1 . 5, 6 The aim of our study was to determine whether TN-C supports platelet adhesion and activation and, thus, could represent an interesting new target for a potentially safer antithrombotic strategy. To investigate the role of TN-C in platelet adhesion and activation, we used both static and dynamic assays. Our study identified a novel role of TN-C as an efficient adhesive and activating protein for platelets. The platelet/TN-C interaction was mediated mainly by integrin ␣ 2 ␤ 1 and the GPIb-IX complex and less by integrin ␣ IIb ␤ 3 . GPIb-IX-mediated adhesion occurred only under flow conditions, was indirect, and depended on the binding of von Willebrand factor (VWF) to TN-C. Finally, the adhesion of platelets to TN-C resulted in their activation, as demonstrated by shape change of the cells and increases in intraplatelet Ca 2ϩ levels.
Methods
An expanded "Methods" section is available in the supplemental data.
In Vitro Static and Dynamic Adhesion Assays
Glass coverslips were coated with 100-g/mL TN-C, fibrinogen (FGN), or VWF for 2 hours at room temperature and blocked with PBS plus 10-mg/mL human serum albumin for 60 minutes. We checked that the protein concentrations used for coating gave maximal platelet adhesion. Washed human platelets in Tyrode's buffer were allowed to adhere to the coated surfaces for 20 or 40 minutes at 37°C, and the adherent cells were processed as previously described. 7 Flow-based experiments were performed using hirudinated whole blood, 100 U/mL, from human or mouse, as previously described. 8
Analysis of Cytosolic Ca 2؉ Fluxes
Platelet intracellular Ca 2ϩ changes were monitored using a quantitative dual-dye ratiometric assay according to a modification of a previously published method. 9
In Vitro TN-C Binding Assay and Immunoprecipitation
ELISA 96-well plates were coated with 1-or 5-g/mL TN-C overnight at 4°C and blocked with PBS plus 20-mg/mL bovine serum albumin for 1 hour at 37°C. Increasing concentrations of VWF in blocking solution were added and incubated for 2 hours at 37°C. To detect bound VWF, a horseradish peroxidase-conjugated anti-VWF antibody was added (0.4 g/mL in blocking solution) for 1 hour at room temperature, and the plates were then incubated with O-phenylenediamine. After 5 minutes of substrate conversion, the reaction was discontinued with 50 L of 3-mol/L H 2 SO 4 and the plates were read at 490 nm.
Purified TN-C and VWF were coincubated (1 mg of TN-C was coincubated with 6.6 mg of VWF and 1 mg of VWF was coincubated with 3.8 mg of TN-C) in 50 L of lysis buffer for 2 hours at 4°C. The protein samples were then incubated with 1 g of an anti-TN-C, anti-VWF, or irrelevant IgG antibody for 1 hour at 4°C, followed by 50 L of 50% (wt/vol) protein G-Sepharose beads for 1 hour at 4°C. Immunoprecipitation experiments and Western blotting were performed as previously described. 10
Statistical Analyses
All values are reported as meanϮSEM unless otherwise indicated. Data were compared by 1-tailed paired t tests when studying the effect of blocking monoclonal antibodies and by 1-tailed unpaired t tests in experiments with mice. Differences were considered significant at PϽ0.05, and all tests were performed using commercially available software (Prism; GraphPad, La Jolla, Calif). 
Results

Washed Platelets Adhere to Immobilized TN-C Under Static Conditions
To determine whether TN-C can interact with platelets, we first evaluated the capacity of this matrix protein to support the adhesion of washed human platelets under static conditions. As shown in Figure 1A , numerous platelets adhered to immobilized TN-C. Interestingly, the number of adherent cells after 40 minutes (3513Ϯ307 platelets/mm 2 ; nϭ3) was similar to that observed on FGN (4296Ϯ681 platelets/mm 2 ; nϭ3), which efficiently binds platelets under static conditions ( Figure 1B) . In contrast, 4.3 times more platelets adhered to TN-C than to VWF (812Ϯ123 platelets/mm 2 ; nϭ3), which is a weak adhesive protein under static conditions 11 but supports efficient platelet adhesion under flow 12 or in the presence of mediators such as botrocetin (8228Ϯ508 platelets/mm 2 ; nϭ3) ( Figure 1B) . These results indicated that platelets adhere to TN-C under static conditions in numbers comparable to those observed on 2 other effective adhesive proteins. Moreover, platelets tended to spread upon attachment to FGN or VWF in the presence of botrocetin, reflecting their activation. In contrast, most of them retained the resting discoid morphology after adhesion to TN-C or VWF without botrocetin ( Figure 1A ).
Platelets Adhere to Immobilized TN-C Under Dynamic Conditions
Next, we explored the capacity of TN-C to support platelet adhesion under flow by perfusing whole blood through glass microcapillaries at wall shear rates found in vessels prone to atherosclerosis, such as the coronary artery (300 s Ϫ1 ). 13 Real-time DIC microscopy showed that, after 8 minutes, the number of adherent cells was 1.9 and 6.2 times higher on TN-C (58 050Ϯ5253 platelets/mm 2 ; nϭ8) than on VWF (30 950Ϯ1539 platelets/mm 2 ; nϭ6) or FGN (9287Ϯ2571 platelets/mm 2 ; nϭ8), respectively ( Figure 2A ). These results pointed to a greater adhesiveness of TN-C compared with VWF or FGN under the shear conditions found in large arteries. Concerning the adhesive behavior, the platelets rolled over VWF (79Ϯ2%; nϭ4) and rapidly detached from FGN (83Ϯ3%; nϭ4), whereas most of them attaching to TN-C remained stationary adherent (87Ϯ4%; nϭ4) ( Figure  2B ). This different behavior probably explains the enhanced platelet accumulation observed on TN-C compared with VWF or FGN (Figure 2A ).
Adhesion to TN-C as a function of wall shear rate exhibited a bell-shaped curve, with maximal adhesion at 1000 s Ϫ1 (49 790Ϯ8629 platelets/mm 2 ; nϭ7) ( Figure 2C and D). Adhesion to VWF similarly increased up to 1000 -15000 s Ϫ1 Figure 2 . Human platelets adhere to immobilized TN-C under dynamic conditions. Hirudinated human whole blood was perfused at various wall shear rates over TN-C, 100 g/mL; FGN, 300 g/mL; or VWF, 100 g/mL. Platelet adhesion was visualized in real time using differential interference contrast (DIC) microscopy. A, The number of adherent platelets at 300 s Ϫ1 was determined during an 8-minute period. B, The adhesive behavior of 40 platelets attaching to the surface during 60 and 90 seconds of perfusion was monitored and expressed as the percentage of adherent platelets. C, Representative DIC microscopy images depicting platelets adhering to TN-C after 3 minutes of perfusion. The bar indicates 14 m. D and E, The total number of adherent platelets (D) and of platelets forming stationary adhesion contacts (E) was counted in 1 random field after 3 minutes of perfusion and expressed as a function of wall shear rate. Data are given as the meanϮSEM of 4 to 8 independent experiments.
(56 600Ϯ2307 platelets/mm 2 ; nϭ3) but remained at a plateau level. As previously described, the adhesion of platelets to FGN was inefficient at shear rates greater than 300 s Ϫ1 . 12 Remarkably, TN-C was more effective than VWF or FGN in the recruitment of stationary adherent platelets, at least up to 1000 s Ϫ1 (Figure 2E ). These findings demonstrated that TN-C efficiently supports platelet adhesion across a wide range of shear rates.
Platelet Adhesion to TN-C Is Primarily Mediated by Integrin ␣ 2 ␤ 1
Blocking the VWF binding site of GPIb-IX or the FGN binding domain of ␣ IIb ␤ 3 (107Ϯ17% and 101Ϯ10% of control, respectively; nϭ3) did not prevent platelet adhesion to TN-C in the static adhesion assay, whereas a pan-blocking anti-␤ 1 antibody significantly reduced it (23Ϯ2% of control; nϭ3; PϽ0.001) ( Figure 3A ). The key role of the ␤ 1 integrin was also demonstrated in the dynamic adhesion assay, in which 2 anti-␤ 1 antibodies (4B4 and P5D2) profoundly inhibited platelet adhesion to TN-C at both 300 s Ϫ1 (by 99.3Ϯ0.3% and 79.0Ϯ6.0%, respectively) and 1500 s Ϫ1 (by 98.4Ϯ1.2% and 99.2Ϯ0.4%, respectively) ( Figure 3B and C).
These results were confirmed in ␤ 1 -deficient mice presenting a 73Ϯ11% (nϭ5, PϽ0.01) reduction in the number of adherent platelets to TN-C at 2500 s Ϫ1 ( Figure 3D ). To identify the integrin subtype involved, adhesion was next evaluated in a mouse strain specifically lacking integrin ␣ 2 ␤ 1 . In ␣ 2 ␤ 1 -deficient platelets, the degree of inhibition was similar to that in ␤ 1 deficiency (77Ϯ14% reduction relative to wild type; nϭ4; PϽ0.05) ( Figure 3D ), indicating that integrin ␣ 2 ␤ 1 is likely to be the main ␤ 1 integrin involved in platelet/TN-C interaction.
Blockade of ␣ v ␤ 3 , which has been proposed as a TN-C receptor on endothelial cells, 6 only slightly reduced platelet adhesion under flow (by 9Ϯ2%; nϭ3; PϽ0.05), suggesting a minor role for this integrin ( Figure 3B ). In contrast, ALMA.12 and AK2, 2 monoclonal antibodies directed against the 45-kDa N-terminal domain of GPIb␣, markedly inhibited platelet adhesion to TN-C at 300 s Ϫ1 (by 64Ϯ10% and 66Ϯ17%, respectively; nϭ3; PϽ0.05), whereas WM23 against the macroglycopeptide region had no significant effect (77Ϯ12% of control; nϭ3; Pϭ0.09) ( Figure 3B ). ALMA.12 reduced platelet adhesion by 95.5Ϯ0.9% at 1500 s Ϫ1 , indicating that the importance of GPIb␣ in TN-C adhesion increases with wall shear rate ( Figure 3C ). In comparison, Integrilin and ReoPro, 2 ␣ IIb ␤ 3 blockers in clinical use, diminished platelet adhesion only under low shear conditions (300 s Ϫ1 ), with 39Ϯ10% and 42Ϯ7% inhibition, respectively (nϭ4, PϽ0.01) ( Figure 3B and C). These findings indicated that the GPIb-IX complex and, to a lesser extent, integrin ␣ IIb ␤ 3 participate in platelet adhesion to TN-C under dynamic, but not static, conditions.
GPIb-Dependent Adhesion of Platelets to TN-C Depends on VWF
The fact that monoclonal antibodies inhibiting VWF binding to GPIb␣ diminished platelet adhesion to TN-C suggested that VWF could serve as an intermediate ligand. This hypoth- Washed human platelets pretreated with prostaglandin E 1 (A) or human whole blood (B and C) were incubated with 10 g/mL of irrelevant mouse IgG (control), 40 g/mL of an integrin ␣ IIb ␤ 3 antagonist (ReoPro or Integrilin), or 10 g/mL of a blocking monoclonal antibody, before being allowed to adhere to TN-C (A) or perfused over TN-C at 300 s Ϫ1 (B) or 1500 s Ϫ1 (C). After 20 minutes, the remaining adherent cells were counted as described in Figure 1 (A) . Adherent platelets were counted after 7 (B) or 3 (C) minutes of perfusion. Adhesion was expressed as a percentage of the adhesion of control platelets set to 100% (A-C). D, Hirudinated whole blood from wild-type, ␤ 1 Ϫ/Ϫ , or ␣ 2 Ϫ/Ϫ mice was perfused over TN-C at 2500 s Ϫ1 , as done in B and C, and adherent platelets were counted after 3 minutes. Data are given as the meanϮSEM of 3 to 5 separate experiments. *PϽ0.05, **PϽ0.01, and ***PϽ0.001. esis was further supported by the ability of 701, an anti-VWF A1 domain monoclonal antibody blocking GPIb␣ binding, to reduce platelet adhesion to TN-C by 27Ϯ7% at 300 s Ϫ1 (nϭ3, PϽ0.05) and by 87Ϯ7% at 1500 s Ϫ1 (nϭ5, PϽ0.001) ( Figure 4A ). Final confirmation of the implication of VWF derived from experiments in VWF-deficient mice, which exhibited decreased adhesion of platelets to TN-C at 2500 s Ϫ1 (by 88Ϯ1%; nϭ4; PϽ0.01) ( Figure 4B ). Overall, these data showed that VWF participates in platelet adhesion to TN-C and that its role intensifies with increasing shear rate.
VWF Binds to Purified TN-C
To further investigate the capacity of VWF to mediate GPIb-dependent adhesion to TN-C, we determined in an ELISA whether these molecules directly interact with each other. As shown in Figure 4C , soluble VWF bound to immobilized TN-C, but not to BSA, reaching saturation at 5 g/mL. The interaction was also observed when both molecules were in solution because immunoprecipitated TN-C coprecipitated with VWF and vice versa ( Figure 4D ). These results demonstrated that VWF interacts with TN-C, thereby supporting a model in which VWF acts as a bridge between TN-C and platelets.
Adhesive Properties of TN-C and VWF Synergize in Platelet Adhesion Under Flow
Because TN-C and VWF were both described to be strongly expressed in atherosclerotic plaques and to more precisely define the functional link between these proteins, we explored the capacity of a combined TN-C-VWF matrix to support platelet adhesion. By using blood from VWF-deficient mice to prevent the participation of plasmatic VWF, we observed a marked enhancement of platelet adhesion to the mixed proteins (17 100Ϯ3051 platelets/mm 2 ; nϭ3; after 2 minutes) at 3000 s Ϫ1 , which was 2.9 and 2.6 times higher than on TN-C (5833Ϯ1073 platelets/mm 2 ; nϭ3; after 2 minutes) or VWF (6533Ϯ1686 platelets/mm 2 ; nϭ3; after 2 minutes) alone, respectively ( Figure 5 ). These results demonstrated that TN-C synergizes with VWF to support platelet adhesion under flow.
Activation of Platelets upon Adhesion to TN-C
Platelet shape change represents 1 of the first measurable signs of activation and results in the transformation of a discoid and smooth resting cell into a spherical form, extending filopodia and ultimately spreading to a "fried egg"-like morphology. Whereas the platelets adhering to TN-C under static conditions tended to remain discoid ( Figure 1A) , most of them became spherical and extended filopodia (82Ϯ4%, nϭ3) at 300 s Ϫ1 , similar to what occurred on VWF (77Ϯ2%, nϭ3) or FGN (75Ϯ4%, nϭ3) ( Figure 6A and B) .
To explore the capacity of TN-C to induce intracellular signaling, we measured cytosolic Ca 2ϩ changes upon adhesion of platelets under flow, using a quantitative dual-dye ratiometric Ca 2ϩ assay. As shown in Figure 6C , whereas individual resting platelets displayed low Ca 2ϩ concentra- tions (Ͻ50 nmol/L), most of those adhering to TN-C exhibited pulsatile and high-frequency Ca 2ϩ spikes ( Figure 6D and E), ranging between 50 and 1650 nmol/L (maximal increase, 363Ϯ55 nmol/L; nϭ50). Platelets adhering to FGN displayed similar variable Ca 2ϩ responses (maximal increase, 383Ϯ61 nmol/L; nϭ40); that were less important on VWF (maximal increase, 167Ϯ31 nmol/L; nϭ40). The increased fluorescence was the result of enhanced cytosolic Ca 2ϩ since pretreating platelets with the Ca 2ϩ chelator DM-BAPTA-AM reduced the mean signal by 96Ϯ1% (nϭ30) ( Figure 6C ). Altogether, these results showed that the adhesion of platelets to TN-C under flow conditions leads to their activation.
Discussion
The studies reported herein identify a novel role of TN-C in platelet physiology and suggest that this extracellular matrix protein could play an important part in atherothrombosis. We provide evidence that TN-C supports efficient platelet adhesion under static and dynamic conditions of up to 1500 s Ϫ1 . Contrary to VWF and FGN, TN-C promoted the stationary adhesion of platelets under flow. We showed that the interaction of platelets with TN-C is a complex process involving at least 3 receptors (ie, integrin ␣ 2 ␤ 1 , integrin ␣ IIb ␤ 3 , and the GPIb-IX complex). Added complexity arises from the fact that platelet attachment to TN-C is in part indirect and occurs through VWF binding. Once attached to TN-C, the platelets become activated, as attested by their shape change and increased intracellular Ca 2ϩ levels.
The data from static adhesion experiments indicated that a platelet surface ␤ 1 integrin bound to TN-C. This is in agreement with previous reports 5, 6 indicating that other cell types, such as endothelial and tumoral cells, interact with TN-C through ␤ 1 integrins, in particular ␣ 2 ␤ 1 , ␣ 8 ␤ 1 , and ␣ 9 ␤ 1 . Platelets contain 3 ␤ 1 integrins (␣ 2 ␤ 1 , ␣ 5 ␤ 1 , and ␣ 6 ␤ 1 ) that bind to collagen, fibronectin, and laminin, respectively.
Integrins ␣ 8 ␤ 1 and ␣ 9 ␤ 1 have not been described in platelets; this was confirmed in Western blotting and RT-PCR assays (data not shown), thereby pointing to ␣ 2 ␤ 1 as the likely candidate for platelet/TN-C interaction. Experiments with genetically modified mice confirmed this hypothesis, providing the first report that another matrix protein than collagen interacts with platelet ␣ 2 ␤ 1 . Although we cannot formally exclude a role of ␣ 5 ␤ 1 and ␣ 6 ␤ 1 , the identical degree of inhibition of platelet adhesion to TN-C in ␣ 2 -and ␤ 1deficient mice suggests that ␣ 2 ␤ 1 is the only ␤ 1 integrin involved. We did not formally demonstrate a direct interaction between ␣ 2 ␤ 1 and TN-C. However, this was strongly suggested because isolated platelets pretreated with prostaglandin E 1 to prevent release of adhesive proteins stored in ␣-granules still efficiently adhered to purified TN-C.
The blockade of ␣ 2 ␤ 1 at high shear resulted in a marked reduction in platelet adhesion, with many fewer platelets attaching to TN-C. This result was surprising because integrins are not usually described as contributing to platelet recruitment under high shear conditions as the result of their slow association rate. 12 Moreover, the few platelets adhering under ␣ 2 ␤ 1 blockade no longer remained stationary but rapidly detached, suggesting that ␣ 2 ␤ 1 also participates in supporting stationary adhesion to TN-C. This is in agreement with the well-recognized role of integrins in stable bond formation as the result of their slow dissociation rates. 12 Two different antibodies blocking collagen binding to ␣ 2 ␤ 1 did not prevent adhesion to TN-C (supplemental Figure II) , indicating distinct binding sites for TN-C and collagen.
Because antibodies preventing VWF binding to GPIb␣ inhibited platelet adhesion to TN-C, GPIb␣ participation was presumably indirect, requiring the prior binding of VWF to TN-C. An analogous mechanism has also been described for platelet adhesion to collagen, which is, in part, mediated through VWF. 14 One difference was that, although human platelets adhered to VWF even at greater than 1500 s Ϫ1 , this was no longer the case for TN-C. This could be the result of a suboptimal amount of TNC-bound plasmatic VWF. Interestingly, normal mouse platelets still efficiently adhered to TN-C at shear rates of up to 2500 s Ϫ1 . The ability of mouse platelets to adhere at higher shear rates when compared with human platelets has also been described on a collagen matrix. 14, 15 This difference could arise from the smaller size of mouse platelets, which reduces the drag forces applied to them, or from different affinities of the receptor-ligand interactions between the 2 species.
Integrin ␣ IIb ␤ 3 is also involved in platelet adhesion to TN-C. This interaction could be indirect through VWF, a known ␣ IIb ␤ 3 ligand, or direct because TN-C contains a region presenting strong homology with the ␥ chain of FGN 16 and an RGD sequence in its third fibronectin type III domain. 17 Unlike GPIb␣, the importance of ␣ IIb ␤ 3 decreased with wall shear rate, which could be because of a low resistance to tensile stress that does not allow ␣ IIb ␤ 3 to withstand high shear. ␣ V ␤ 3 , the second platelet ␤ 3 integrin, mediates endothelial and tumoral cell adhesion to TN-C 5,6 but is not critical in platelet/TN-C interaction. This could be explained by its low expression (250 receptors per platelet) compared with integrin ␣ IIb ␤ 3 (80 000 receptors per platelet).
Platelets adhering to TN-C became activated as indicated by their shape change and intracellular Ca 2ϩ oscillations, suggesting that the role of TN-C goes beyond its ability to recruit platelets. Because the GPIb/VWF interaction triggers filopodia extension and transient Ca 2ϩ events, 8 it could be implicated in the TN-C response. In addition, outside-in ␣ 2 ␤ 1 and ␣ IIb ␤ 3 signaling also induce morphological changes and elevated Ca 2ϩ oscillations in platelets. 8, 18 Given that Ca 2ϩ was measured in the absence of plasma VWF, it points to a likely role of ␣ 2 ␤ 1 in our assay conditions. This would agree with the similar Ca 2ϩ oscillations observed herein on TN-C and in platelets adhering to the ␣ 2 ␤ 1 -specific GFOGER peptide. 18 Future studies are required to determine the contribution of the different receptors and of the additional amplification by soluble agonists, such as ADP or thromboxane A 2 , which are released by activated platelets.
Platelets efficiently adhered to TN-C across a wide range of wall shear rates, with maximal adhesion at approximately 1000 s Ϫ1 to 1500 s Ϫ1 . So far, VWF 12 , collagen 14 and thrombospondin-1 were the only adhesive proteins known to support human platelet adhesion under high shear; the other matrix proteins, including FGN and fibronectin, do not display this property. The shear conditions under which platelets interact with TN-C are of pathological relevance because 1000 s Ϫ1 represents the mean peak wall shear rate found in diseased carotid arteries presenting 78% stenosis. 19 Given that 60% stenosis is clinically rated as significant and 70% is rated as severe, 20 the TN-C exposed upon plaque erosion or rupture could participate in platelet recruitment. Moreover, even in the case of very severe stenosis (Ͼ90%), local regions of low shear (Ͻ1000 s Ϫ1 ) extend into the downstream expansion zone, 19 where TN-C could also participate in the first step of thrombus growth.
Pharmacologically, blocking platelet/TN-C interaction could inhibit the initial stage of platelet recruitment and activation on a ruptured plaque and thereby potentially prevent excessive thrombosis. Because TN-C is almost absent in healthy vessels, 2-4 agents blocking platelet/TN-C interaction might be expected to be highly selective for thrombosis and would not affect normal hemostasis. This possibility is supported by the fact that TN-C-deficient mice present a normal tail bleeding time (M.S., unpublished data, 2010). From a clinical point of view, an agent that prevents recruitment of platelets to a site of plaque rupture without affecting hemostasis would, in theory, provide a wide therapeutic window with a minor risk of bleeding.
Based on the present findings, the following working model is proposed. Upon erosion or rupture of an atherosclerotic plaque, TN-C present at high levels will become exposed to circulating blood, bind plasmatic VWF, and Figure 6 . TN-C induces platelet shape change and increases in intracellular calcium. A and B, Human whole blood was perfused at 300 s Ϫ1 over TN-C, FGN, or VWF. The morphology of adherent platelets was examined by differential interference contrast (DIC) microscopy (A), and the percentage of spherical platelets extending filopodia was quantified for each matrix (B). The bar indicates 6 m. Data in B represent the meanϮSEM in 1 random field in 3 independent experiments. C through E, Washed human platelets loaded with Ca 2ϩ and morphological dyes were reconstituted with 50% (vol/vol) autologous packed red blood cells at a final concentration of 250ϫ10 6 platelets per milliliter in the presence of either vehicle (dimethyl sulfoxide [control]) or 50-mol/L DM-BAPTA-AM and perfused over TN-C, FGN, or VWF at 300 s Ϫ1 , as in A and B. The changes in fluorescence in individual adherent platelets were monitored for 8 minutes by confocal microscopy, and Ca 2ϩ concentrations were determined. In C, the dot plot distribution of the relative maximal increase in cytosolic Ca 2ϩ in individual platelets adhering to TN-C, FGN, or VWF is shown. Resting refers to washed platelets allowed to adhere to nonreactive 10-mg/mL BSAcoated coverslips. The thick solid lines represent the mean Ca 2ϩ increase, and results are from 4 to 5 independent experiments. D, Typical Ca 2ϩ profile of 1 representative platelet adhering to TN-C. E, Single-channel Oregon green fluorescence images depicting Ca 2ϩ oscillations of a representative platelet adhering to TN-C. The bar indicates 2 m. capture circulating platelets through interaction with the GPIb-IX complex. Exposed TN-C will also recruit platelets through direct interaction with integrin ␣ 2 ␤ 1 . Stable adhesion will be established through integrins, primarily ␣ 2 ␤ 1 and ␣ IIb ␤ 3 , that bind to VWF and/or TN-C. Finally, engagement of these different receptors will induce platelet activation, resulting in shape change and increase in intracellular Ca 2ϩ levels.
The full implication of TN-C in thrombosis and its importance with respect to other pathways remain to be clearly delineated. The observation that platelets do not form aggregates on TN-C suggests that it might be much less thrombogenic than highly reactive plaque components, such as collagen, lipid derivatives, or tissue factor. Rather, we postulate that TN-C could provide additional contacts increasing platelet-vessel wall interaction and platelet activation upon plaque rupture. In particular, the fact that platelet recruitment under flow was greatly enhanced on a mixed TN-C-VWF substrate compared with individual proteins strongly suggests that TN-C could act in combination with other platelet-reactive components to promote full integrin ␣ IIb ␤ 3 activation and efficient thrombus growth.
In conclusion, this previously unrecognized role of TN-C in platelet adhesion and activation could be of great significance in the context of the shear conditions encountered in arterial thrombosis. This study provides an interesting candidate to put into practice the concept of targeting plateletreactive components preferentially expressed in atherosclerotic plaques to develop a safer antithrombotic treatment.
